Bryan Johnson: I Just Took the Most Powerful Dose of DMT in the World... Here's What It Was Like

In this solo episode, Bryan Johnson joins the All-In crew to discuss his recent experience with 5-MeO-DMT, one of the world's most powerful psychedelics. David Friedberg introduces the conversation by contextualizing Johnson's extreme approach to biohacking and longevity optimization. Johnson explains his motivations for taking the substance, detailing the careful preparation and scientific approach he took to what many would consider an extraordinarily risky experiment. He frames the experience within his broader mission to understand and optimize human biology and consciousness. The conversation then shifts to what brain imaging technology can actually tell us about psychedelic experiences. Johnson and the hosts discuss functional MRI scans, EEG measurements, and other neuroimaging tools that purport to show what happens in the brain during these states. The discussion reveals significant gaps between what people report subjectively during psychedelic experiences and what the objective measurements actually show, raising important questions about the nature of consciousness and measurement itself. A substantial portion of the episode focuses on the psychological risks associated with powerful psychedelics. Johnson addresses concerns about psychosis, bad trips, and the very real possibility that such experiences can catalyze major life-altering decisions that may or may not be beneficial. The hosts probe whether the insights gained justify the risks taken and whether there are safer ways to achieve similar cognitive or spiritual breakthroughs. The conversation then pivots to Johnson's broader vision for human optimization, specifically discussing organoids and gene therapy as emerging frontiers. These technologies represent potential methods to engineer biological improvements at a fundamental level, moving beyond pharmaceuticals and supplements to actually rewriting biological code. Johnson explains how these approaches differ from current longevity interventions and why they represent the true next frontier in human enhancement. The discussion of GLP-1 drugs like Ozempic explores how pharmaceutical interventions are reshaping human optimization and health. The hosts debate whether abundance in healthcare technology is creating new possibilities for human flourishing or exacerbating inequality. Finally, Johnson identifies what he believes is an underappreciated longevity compound or intervention that most people in the biohacking and longevity space haven't adequately focused on. The episode concludes with a forward-looking discussion about the trajectory of human optimization and whether we're entering a new era where radical life extension and cognitive enhancement become achievable goals.